Journal
ONCOTARGET
Volume 8, Issue 34, Pages 56158-56167Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.19341
Keywords
KIT; GIST; novel deletion mutation; Imatinib; neoadjuvant treatment
Categories
Funding
- Italian Association for Cancer Research (AIRC IG) [17413]
- Anatomic Pathology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
- Italian Ministry of Health (5 per Mille) of IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
Ask authors/readers for more resources
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs express the receptor tyrosine kinase KIT, and the majority of GISTs present KIT gain-of-function mutations that cluster in the 5' end of the receptor juxtamembrane domain. On the other hand, little information is known about GISTs carrying mutations in the 3' end of the KIT juxtamembrane domain. Here we report and discuss a clinical case of localized duodenal GIST whose molecular characterization revealed the presence of a new 21 nucleotide/7 amino acid deletion in the 3' end of KIT juxtamembrane domain (Delta 574-580). The patient was treated with Imatinib at standard regimen dose (400 mg/day), and responded well as the original tumor mass reduced, ultimately allowing conservative surgery. In line with these clinical evidences computer simulations, biophysical techniques and in vitro experiments demonstrated that the receptor tyrosine kinase KIT carrying the Delta 574-580 mutation displays constitutive phosphorylation, which can be switched-off upon Imatinib treatment. In addition, results from this study showed that a clinical useful procedure, neoadjuvant treatment, can occasionally be of value for the understanding of the molecular pathogenesis of GIST.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available